Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Valuation of SESEN prior to FDA rejection

<< Previous

Bullboard Posts

Next >>

Post by ScienceFirston May 18, 2023 9:49am

282 Views

Post# 35454315

Valuation of SESEN prior to FDA rejection

Market valuation of SESEN prior to the the FDA rejection in August 2021.

Lets just focus on the ride that led it from 60M$US (June 2020) to 210M$US (Dec. 2020) to 400M$US (March 2021).

The rest, to 800M$US, is just icing on the cake, as they were applying for full FDA approval. Upon full FDA approval, it would have grown to around 2B$US.